Hospital Universitario de Basurto-ko ikertzaileekin lankidetzan egindako argitalpenak (14)

2024

  1. Beyond cancer treatment: dermo-aesthetic and other wellness recommendations for breast cancer patients

    Clinical and Translational Oncology

  2. First-line therapy with palbociclib in patients with advanced HR+/HER2− breast cancer: The real-life study PALBOSPAIN

    Breast Cancer Research and Treatment, Vol. 206, Núm. 2, pp. 317-328

  3. Leveraging Large Language Models for Precision Monitoring of Chemotherapy-Induced Toxicities: A Pilot Study with Expert Comparisons and Future Directions

    Cancers, Vol. 16, Núm. 16

2023

  1. Narrative Review of Multidisciplinary Management of Central Nervous Involvement in Patients with HER2-Positive Metastatic Breast Cancer: Focus on Elderly Patients

    Advances in Therapy, Vol. 40, Núm. 8, pp. 3304-3331

2022

  1. Safety and efficacy of ribociclib plus letrozole in patients with HR+, HER2– advanced breast cancer: Results from the Spanish sub-population of the phase 3b CompLEEment-1 trial

    Breast, Vol. 66, pp. 77-84

2021

  1. Consensus of the Spanish society of laboratory medicine and the Spanish society of medical oncology on the methodology and criteria for evaluation of circulating tumour markers in breast cancer

    Clinical and Translational Oncology, Vol. 23, Núm. 7, pp. 1272-1280

2020

  1. Probabilistic cost-utility analysis and expected value of perfect information for the Oncotype multigenic test: a discrete event simulation model

    Gaceta Sanitaria, Vol. 34, Núm. 1, pp. 61-68

  2. The economic burden of metastatic breast cancer in Spain

    European Journal of Hospital Pharmacy , Vol. 27, Núm. 1, pp. 19-24

2018

  1. Clinical and economic impact of the 21-gene recurrence score assay in adjuvant therapy decision making in patients with early-stage breast cancer: Pooled analysis in 4 basque country university hospitals

    ClinicoEconomics and Outcomes Research, Vol. 10, pp. 189-199

  2. Cost-effectiveness analysis of ribociclib versus palbociclib in the first-line treatment of HR+/ HER2– advanced or metastatic breast cancer in Spain

    ClinicoEconomics and Outcomes Research, Vol. 10, pp. 773-790

2017

  1. Effectiveness and safety of Eribulin in metastatic breast cancer

    European Journal of Clinical Pharmacy, Vol. 19, Núm. 1, pp. 55-59

2016

  1. Albumin-Bound (NAB) Paclitaxel, Abraxane®

    The Easy Book of Cancer Pharmacology (Nova Science Publishers, Inc.), pp. 7-17

  2. Docetaxel.Taxotere®

    The Easy Book of Cancer Pharmacology (Nova Science Publishers, Inc.), pp. 139-145

  3. Gemcitabine. Gemzar®

    The Easy Book of Cancer Pharmacology (Nova Science Publishers, Inc.), pp. 197-205